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SUMMARY
Interleukin-21 (IL-21) is a pleiotropic cytokine that induces expression of transcription factor
BLIMP1 (encoded by Prdm1), which regulates plasma cell differentiation and T cell homeostasis.
We identified an IL-21 response element downstream of Prdm1 that binds the transcription factors
STAT3 and IRF4, which are required for optimal Prdm1 expression. Genome-wide ChIP-Seq
mapping of STAT3- and IRF4-binding sites showed that most regions with IL-21-induced STAT3
binding also bound IRF4 in vivo and furthermore revealed that the noncanonical TTCnnnTAA
GAS motif critical in Prdm1 was broadly used for STAT3 binding. Comparing genome-wide
expression array data to binding sites revealed that most IL-21-regulated genes were associated
with combined STAT3-IRF4 sites rather than pure STAT3 sites. Correspondingly, ChIP-Seq
analysis of Irf4−/− T cells showed greatly diminished STAT3 binding after IL-21 treatment, and
Irf4−/− mice showed impaired IL-21-induced Tfh cell differentiation in vivo. These results reveal
broad cooperative gene regulation by STAT3 and IRF4.
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INTRODUCTION
B lymphocyte-induced maturation protein-1 (BLIMP1) is a transcriptional repressor that
was discovered as a zinc finger protein expressed upon plasmacytic differentiation of the
Bcl-1 B cell lymphoma line (Turner et al., 1994). BLIMP1 is encoded by the PRDM1 gene
in humans and the Prdm1 gene in mice. BLIMP1 regulates terminal differentiation of
plasma cells in which it represses the expression of the Bcl6 and Pax5 genes (Martins and
Calame, 2008); BCL6 in turn can repress Prdm1 expression (Shaffer et al., 2000). BLIMP1
has been most thoroughly studied in a B cell context, but it is also expressed in T cells,
granulocytes, macrophages, epithelial cells, and germ cells and regulates T cell homeostasis
and peripheral tolerance (Kallies et al., 2006; Martins et al., 2006; Ohinata et al., 2005).
Interleukin-21 (IL-21) is a type I cytokine produced after T cell activation that is most
related to IL-2, IL-4, and IL-15 (Parrish-Novak et al., 2000; Spolski and Leonard, 2008).
The IL-21 receptor was discovered as an orphan receptor (Ozaki et al., 2000; Parrish-Novak
et al., 2000). Like IL-2, IL-4, IL-7, IL-9, and IL-15, IL-21 shares the common cytokine
receptor γ chain, γc, as a critical receptor component (Spolski and Leonard, 2008). γc is
encoded by the IL2RG gene, mutation of which results in X-linked severe combined
immunodeficiency in humans, a disease in which T and NK cells are absent and B cells are
present but nonfunctional (Leonard, 2001; Noguchi et al., 1993). IL-21 receptors are
expressed by T cells, B cells, NK cells, myeloid cells, and keratinocytes, corresponding to
pleiotropic actions of IL-21 on multiple lineages. IL-21 can act as a comitogen for T cells
(Parrish-Novak et al., 2000), can potently drive CD8+ T cell expansion when combined with
IL-7 or IL-15 (Zeng et al., 2005), and promotes the differentiation of T helper 17 (Th17)
CD4+ T cells (Spolski and Leonard, 2008) and development of T follicular helper (Tfh) cells
(Nurieva et al., 2008; Vogelzang et al., 2008). Within the B cell lineage, IL-21 critically
regulates immunoglobulin production, particularly IgG1, and mice lacking expression of
both IL-4 and IL-21R exhibit defective germinal center development and pan-
hypogammaglobulinemia, which is likely to explain the B cell phenotype in humans with
XSCID (Ozaki et al., 2002). Moreover, IL-21 potently induces BLIMP1 and plasma cell
differentiation (Ozaki et al., 2004).
We have elucidated the molecular basis for IL-21-mediated BLIMP1 induction by finding
an IL-21 response element 3′ of the Prdm1 gene whose activity requires both STAT3 and
IRF4. STAT3 (signal transducer and activator of transcription 3) and IRF4 (interferon
regulatory factor-4) mediate signaling in response to a range of cytokines, including IL-21
(Zeng et al., 2007; Huber et al., 2008). IRF4 is a lymphocyte-restricted transcription factor
that is part of a family of DNA-binding proteins critical for the function and homeostasis of
mature B and T cells, as well as for the development of subpopulations of dendritic cells
(Gabriele and Ozato, 2007; Tamura et al., 2008). We identified a functional cooperation
between STAT3 and IRF4 in IL-21-induced Prdm1 expression, extending the range of
known actions for IRF4. Moreover, Solexa-based ChIP-Seq genome-wide analyses revealed
that most genomic areas binding STAT3 after IL-21 treatment also constitutively bind IRF4
and that there was greatly diminished STAT3 binding in the absence of IRF4. We
demonstrate that the expression of other IL-21-regulated genes also depends on both STAT3
and IRF4, revealing the broad functional cooperation of these transcription factors. Finally,
we showed that the Prdm1 IL-21 response element uses a single-nucleotide variant
(TTCnnnTAA) of the canonical TTCnnnGAA STAT3 motif, and this variant is a broadly
used GAS motif in the genome.
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RESULTS
IL-21 Rapidly Induces Prdm1 Gene Expression
We previously showed that IL-21 can induce BLIMP1 expression (Ozaki et al., 2004), and
indeed, IL-21 can induce Prdm1 expression in multiple B lymphoma lines (Figure 1A).
When primary splenic B cells were preactivated with anti-CD40, with or without anti-IgM,
and rested, subsequent IL-21-induced Prdm1 expression was higher in cells preactivated
without anti-IgM (Figure 1B). IL-21 also induced BLIMP1 expression in preactivated B
cells (Figure 1C). Induction of Prdm1 mRNA was seen by 1 hr, with peak mRNA
expression typically at 24 hr (Figure S1A and S1B available online). LPS also induced
Prdm1 expression, whereas IL-4 did not (Figure S1B). IL-21 reproducibly induced Prdm1
gene expression slightly more quickly than did LPS, although LPS was more potent in its
effect at 48 hr (Figure S1B).
An IL-21 Response Element Is 3′ of the Prdm1 Gene
To identify an IL-21-responsive region, we transfected NFS201 cells with a series of Prdm1
luciferase reporter constructs (Figure 1D). A “full-length” construct denoted R1 (reporter
construct 1) extending from −10.2 to +29.4 kb relative to the main transcription start site
(TSS) exhibited IL-21-induced activity, but a series of smaller constructs, R2–R7, did not
(Figures 1D and 1E). We digested R1 with restriction enzymes to generate internal deletion
constructs R8, R9, and R10 (Figure 1D). Of these, only R9 exhibited IL-21-induced
luciferase activity (Figure 1E), indicating that the IL-21 response region is between 22.3 and
28.0 kb. Indeed, construct R11 containing this specific region 5′ to the Prdm1 minimal
promoter (Figure 1D) responded to IL-21 in NFS201 cells and primary splenic B cells
(Figure 1F).
We therefore generated deletion mutants of R11 (Figure 1G). 5′ deletion to 26.0 kb
(constructs R12 to R17) exhibited IL-21-induced activity, but further deletion (R18 and
R19) greatly diminished IL-21-induced activity. With 3′ deletion mutants, R22 retained
activity, but R20 and R21 did not. Together, the activities of R17 and R22 indicated the
critical role of the 26 to 26.5 kb region. Moreover, R23 and R25, which lack this region,
were inactive, whereas R24 and R26 reporters, which span this region, potently responded to
IL-21 (Figure 1G). Furthermore, deletion of the 26–26.5 kb region from R11 to yield R27
abrogated IL-21-induced activity (Figure 1G). To refine the mapping, we generated deletion
mutants of R26 (Figure 1H). 5′ deletion to 26.2 kb (R31) retained activity but deletion to
26.3 kb (R32) eliminated activity. 3′ deletion to 26.4 kb (R33) lowered basal activity (open
bar) but not inducibility (closed bar), whereas deletion to 26.3 kb (R34) or beyond (R35)
eliminated IL-21-induced activity. Thus, both the 26.2–26.3 kb and 26.3–26.4 kb regions
were essential, and R36 and R37, which span the 26.2 to 26.4 kb region, both exhibited
substantial activity, whereas smaller fragments (R38, R39, and R40) had greatly decreased
activity. These data were consistent with two factors binding within the 212 bp region
(extending from +4678 to +4889 relative to the ATTAAA polyadenylation signal of the
Prdm1 gene; see NM_007548.3), one in the R38 region and one in the R40 region, to
mediate IL-21-induced Prdm1 expression.
STAT3 and IRF4 Bind to the Prdm1 IL-21 Response Element In Vivo
IL-21 can activate STAT1, STAT3, and STAT5, with STAT3 being the most important for
IL-21 signaling (Diehl et al., 2008; Zeng et al., 2007). We used transcription-factor-binding
prediction software (MatInspector) to identify potential γ-interferon-activated sequence
(GAS) motifs that can bind these STATs (Levy and Darnell, 2002). Canonical GAS motifs
have a TTCnnnGAA sequence, but the 212 bp Prdm1 IL-21 response element has a single-
nucleotide variant TTCCAGTAA motif (underlined in Figure 2A). Electrophoretic mobility
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shift assays (EMSAs) with NFS201 nuclear extracts and a WT probe (probe #1 in Figure
2A) revealed an IL-21-induced complex (Figure 2B, lane 2, solid arrow), but not when the
motif was mutated to agaCAGTAA (lane 4). The complex was super-shifted by anti-STAT3
but not by antibodies to STAT1, STAT5A, or STAT5B (lanes 5–8). IL-21 also induced
formation of a faster mobility complex (lane 2, open arrow) whose intensity was enhanced
with the mutant probe (lane 4). Examination of the DNA sequence revealed a putative IRF-
binding motif (Tamura et al., 2008) (TTTC, boxed in Figure 2A) immediately 3′ of the
STAT3-binding site. Indeed, anti-IRF4 super-shifted the faster complex, whereas anti-
STAT3 did not (Figure 2B, lanes 9–11), indicative of IRF4 binding.
To further investigate binding to the 212 bp IL-21 response element, we performed EMSAs
with a series of 30 bp probes spanning this region. We found IL-21-induced complexes to
two other probes, #2 and #3 (Figures 2C), which also contain putative TTTC IRF-binding
motifs (boxed in Figure 2A). When we mutated the TTTC motifs to gagC, DNA-protein
complexes were no longer observed (Figure 2C, lanes 3 and 4 versus 1 and 2). Moreover,
complex formation was blocked and/or super-shifted by antibodies to IRF4 and IRF8.
Signals were stronger with probe #3 than #2, perhaps because the GTTTC sequence is better
than TTTTC for binding IRF4. We also tested antibodies to PU.1, a cofactor for IRF4
(Eisenbeis et al., 1995), but no supershift was observed (Figure 2C).
To evaluate STAT3, IRF4, and IRF8 binding in vivo, we used splenic B cells and chromatin
immunoprecipitation (ChIP). IL-21 induced binding of STAT3 and IRF4 but not of IRF8 to
the Prdm1 gene (Figure 2D), whereas none of these factors bound to a control intronic
region of the mouse β-actin (Actb) gene (data not shown). Thus, STAT3 and IRF4 bind to
the Prdm1 response element in primary B cells in vivo.
STAT3 and IRF4 Are Critical for IL-21-Induced Prdm1 Expression in B Cells
We next studied the role of STAT3 in IL-21-induced Prdm1 expression. When we mutated
the TTCCAGTAA STAT3 site to agaCAGTAA (Mut1, Figure 3A), IL-21-induced
luciferase activity was markedly reduced (R37-Mut1 in Figure 3B). Moreover, Prdm1
mRNA expression was lower in splenic B cells from Stat3f/f-CD19-Cre+/− mice, which lack
STAT3 (Figure 3C), and correspondingly, IL-21-induced activity of the R37 construct was
markedly reduced in these cells (Figure 3D). Thus, STAT3 was essential for activity of the
Prdm1 IL-21 response element. IL-21 receptor expression was also slightly low in Stat3f/f-
CD19-Cre+/− B cells (Figure 3E).
We next separately mutated the IRF motifs from TTTC to gagC in the context of R37
(Figure 3A). The Mut2 mutation did not affect IL-21-induced luciferase activity, whereas
Mut3, Mut4, and Mut5 (combination of Mut3 and Mut4) lowered activity, and simultaneous
mutation of Mut3, Mut4, and the GAS motif (Mut6) dramatically decreased inducible
activity (Figure 3B). We found greatly diminished IL-21-induced Prdm1 mRNA expression
in Irf4−/− but not Irf8−/− B cells (Figure 3F, left panel), whereas IL-21-induced Pim1
expression was not diminished in either Irf4−/− or Irf8−/− B cells (right panel). There was no
difference in IL-21R expression in Irf4−/− versus WT B cells (Figure 3G), and IL-21 slightly
induced Irf4 expression (Figure 3H). Because IRF4 and PU.1 can interact (Eisenbeis et al.,
1995; Tamura et al., 2008), we also examined the IL-21-induced Prdm1 expression in
Sfpi1f/f-CD19-Cre+/− B cells and (Sfpi1 is the gene that encodes PU.1) found similar Prdm1
expression to wild-type (WT) cells (Figure 3I). IL-21R expression in Sfpi1f/f/CD19-Cre+/− B
cells was similar to that in the WT control (Figure 3J). Thus, IRF4, but not PU.1 or IRF8, is
required for Prdm1 expression.
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IL-21-Induced Prdm1 Gene Expression in T Cells Is Dependent on STAT3 and IRF4
We next examined Prdm1 induction in preactivated splenic T cells. Whereas IL-2, IL-5,
IL-6, IL-10, and IFN-γ had little if any effect, IL-4 induced Prdm1 expression, and IL-21
was the most potent inducer in both CD4+ (Figure 4A) and CD8+ T cells (Figure 4B), with
more rapid Prdm1 induction than was seen with IL-4. IL-21 also induced BLIMP1 protein
(Figure 4C). As in B cells, IL-21 markedly increased activity of the 212 bp R37 reporter in T
cells, and mutation of the GAS motif (Mut1) or IRF motifs (Mut5) or both together (Mut6)
decreased activity (Figure 4D). ChIP experiments confirmed STAT3 and IRF4 binding to
the IL-21 response element in splenic CD4+ T cells (Figure 4E), with no binding of these
factors to an intronic region of the Actb gene (data not shown). IL-21-induced Prdm1
expression was abrogated in splenic Stat3-deficient CD4+ T cells (Figure 4F) and markedly
diminished in CD4+ and CD8+ T cells from Irf4−/− but not Irf8−/− mice (Figures 4H and 4I).
IL-21R expression was not altered in Stat3-deficient and Irf4−/− T cells (Figure 4G and 4J).
In contrast to B cells, IL-21 markedly induced Irf4 mRNA expression in CD4+ T cells at 1
hr (Figure 4K). Although IL-21, IL-6, and IL-10 each activated STAT3, IL-21 was most
potent (Figure 4L), corresponding to its more potent induction of Prdm1 (Figure 4A) and
Socs3 (Figure 4M) expression. At 6 hr, IL-6-, IL-10-, and IL-21-induced Socs3 expression
was reduced in Irf4−/− CD4+ T cells (Figure 4M).
Because STAT3 and IRF4 both bind to the IL-21 response element and functionally
cooperate for Prdm1 expression, we hypothesized that these proteins might associate.
Although we saw weak coprecipitation in some experiments, this was not reproducible (data
not shown), consistent with the lack of interaction reported in another study that used
STAT3 as a negative control for coprecipitation with IRF4 (Gupta et al., 1999). Thus, if
STAT3 and IRF4 interact, the association is either transient or unstable under the
experimental conditions used.
STAT3 and IRF4 Often Bind to Overlapping Sites on the Genome
Because STAT3 and IRF4 cooperatively activated the Prdm1 IL-21 response element, we
investigated the extent to which binding sites for these factors colocalized. Using ChIP
followed by Solexa-based sequencing (Chip-Seq), we mapped (see Experimental Procedures
and Supplemental Experimental Procedures and Figures S4 and S5 for details) the STAT3-
and IRF4-binding sites on the whole genome in CD4+ T cells that were preactivated, rested,
and not treated or treated with IL-21. A total of 4.7 to 6.3 million uniquely mapped tags
were obtained from two independent experiments that were merged (Table S1). We
identified (see Experimental Procedures) 4,422 STAT3 and 18,883 IRF4 sites, covering 1.74
Mb and 7.36 Mb (0.07% and 0.3% of the genome), respectively. Strikingly, the binding
profiles of STAT3 and IRF4 strongly overlapped: 76% of the STAT3-binding regions also
bound IRF4 (Figure 5A). The a priori probability of this level of colocalization is very low
(p < 10−5000). Table S2 shows for all STAT3-binding sites the characteristics of the peaks,
their coordinates on the genome, the number of STAT3 and IRF4 tags at each site before
and after IL-21 treatment, and the list of neighboring genes, which are candidates for
regulation by STAT3 and IRF4.
As expected, IL-21 induced STAT3 binding (4397 sites after IL-21 versus 335 before). In
contrast, similar numbers of IRF4-binding sites were seen before (14,306) and after (15,408)
IL-21 treatment, and their genome-wide pattern was partly reorganized (Figures 5A). The
fact that 64% of the sites where STAT3 bound after IL-21 treatment were occupied by IRF4
prior to IL-21 suggested that IRF4 might promote recruitment of STAT3, and the strong
overlap of STAT3- and IRF4-binding sites suggested that these factors might broadly
cooperate to regulate gene expression.
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High-Resolution Mapping of STAT3- and IRF4-Binding Sites in the Prdm1 Gene
We found that the genome-wide ChIP-Seq data corroborated and extended our
characterization of the Prdm1 IL-21 response element. STAT3 and IRF4 both bound to the
212 bp IL-21 response element (Figure 5B), and the maxima of the ChIP-Seq tag densities
lie within a few base pairs of the motifs we had defined. The STAT3 peak coincides with the
TTCCAGTAA motif (#2 blue region in Figure 5B and sequence below) and the two IRF4
main peaks coincide with the TTTC motif (underlined in the blue region) and the GTTTC
motif (#3 yellow region). A secondary IRF4-binding site (#1 gray region) was also
observed. The pattern suggests that IL-21 induces STAT3 binding and a rearrangement of
IRF4 binding nearby. Interestingly, additional STAT3 and IRF4 sites were found in the
Prdm1 gene (Figure 5C and Table S2; see Table S10 for all IRF4-binding sites in mouse
CD4+ T cells), but their functional significance was not indicated by our Prdm1 reporter
assays (Figures 1E and 1F).
Correlation of STAT3- and IRF4-Binding Sites with IL-21-Regulated Genes
Given the functional cooperation of STAT3 and IRF4 for IL-21-induced Prdm1 expression,
we investigated whether this extended to other genes. We performed an Affymetrix gene
expression analysis (Figures S2 and S3 and Table S3) using preactivated T cells induced by
IL-21 for 0, 1, 6, and 24 hr. Five biological replicas at each time point gave highly consistent
results. With a fold change of ≥ 1.5 at p ≤ 0.001, 2322 genes were regulated by IL-21,
which included well-recognized STAT3-regulated genes such as Socs3 and Bcl3.
To identify which IL-21-regulated genes might be regulated by STAT3, we identified those
“within reach” of a STAT3-binding site by ChIP-Seq analysis. Because transcriptional
regulators can bind upstream, within, or downstream of target genes, and act from a
distance, knowing binding-site locations does not necessarily indicate their importance for
gene regulation. Nevertheless, genes with such sites were reasonable candidates. On the
basis of the ChIP-Seq experiments, 811 of the 2322 IL-21-regulated genes (Table S4) were
associated with 1682 STAT3-binding sites, or an average of approximately two STAT3 sites
per IL-21-regulated gene. Most of these sites (1308 or 78%) also bound IRF4, and we
observed a cooperative effect of IRF4 on STAT3 binding and vice versa: sites binding both
STAT3 and IRF4 had on average twice as many tags for each protein as sites binding only
STAT3 or IRF4.
We next examined the location of the STAT3 and IRF4 sites relative to the IL-21 regulated
genes by using gene annotations defined in AceView (Thierry-Mieg and Thierry-Mieg,
2006), which includes all experimentally supported alternatively spliced transcripts. STAT3-
binding sites lie inside 63% of the regulated genes, upstream of 41%, and downstream of
25% (Tables S5, S6, and S7, respectively); this sums to >100%, reflecting the frequent
presence of several STAT3 sites in more than one location relative to a given gene. The sites
are broadly distributed, but with a relative enrichment in the promoter area, with 14% of
sites between 2 kb 5′ upstream and 1 kb downstream of the most 5′ TSS (Figure S7). The
broad distribution is consistent with the ability of STATs to act at a distance, as for example
is seen in the IL2RA gene (Kim et al., 2001). Interestingly, similar to the Prdm1 site, STAT3
sites located downstream of genes more often exhibit IRF4 cobinding (96%, 329 of 345
sites) than sites within (71%, 600 of 850 sites) or upstream (78%, 422 of 543 sites) of genes.
Strikingly, 310 of the 811 IL-21 sensitive genes near a STAT3-binding site were previously
associated to a phenotype by MGI annotation (Table S4): 199 genes (25%) have particularly
interesting phenotypes, given that the genetic defects affect the immune system (180 genes)
or the hematopoietic system (145 genes) or lead to carcinogenesis (44 genes), as compared
to only 5% of 33,774 genes tested on the Affymetrix chip. When we integrated in AceView
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the tissues of origin of the cDNA libraries reported in GenBank and dbEST, we found that
791 of the 811 IL-21-regulated genes (98%) with a STAT3 site nearby were expressed
within lymphoid tissues versus 66% of genes on the Affymetrix chip.
STAT3 and IRF4 Broadly Cooperate to Mediate IL-21-Induced Gene Expression in CD4+ T
Cells
To extend our findings, we selected a number of genes induced >1.5-fold with colocalization
of STAT3 and IRF4 binding (a list of these genes is in Tables S5–S7). As shown in Figure
6A (open bars), IL-21 significantly enhanced the expression of Socs3, Bcl3, and Tha1 in
CD4+ T cells from WT littermate controls, but their induction was diminished in cells from
Irf4−/− mice (solid bars) and Stat3−/− mice (data not shown). This is consistent with closely
positioned STAT3- and IRF4-binding sites in these genes (Figures 6B) and establishes that
STAT3 and IRF4 more broadly functionally cooperate (see Figure S9 for the sequences
spanning the regions in the Socs3, Bcl3, and Tha1 genes that are depicted in Figure 6B).
We next partitioned the genes into those “within reach” of either a composite site binding
both STAT3 and IRF4, of two independent sites with one binding STAT3 and the other
IRF4, of a site binding STAT3 or IRF4 alone, or near no candidate site. Interestingly, genes
whose expression was regulated by IL-21 (>1.5-fold change in the Affymetrix array) were
much more frequently found in the vicinity of composite sites (Table S8). A chi-square
analysis revealed that over the entire genome, the cooperative binding of STAT3 and IRF4
to the same sites correlates with a greater propensity to mediate IL-21-induced regulation of
gene expression as compared to sites binding only STAT3 (p = 3 × 10−4). Moreover, a
chromosomal map depicting the location of STAT3 and IRF4 sites throughout the genome
reveals the high frequency of association of IRF4 with STAT3 and the rarity of apparently
functional STAT3 sites that exist in the absence of IRF4 (Figure S6). Very close binding of
STAT3 with IRF4 was evident in a genome-wide fashion (Figure 6C). The interesting “dip”
in the peak (arrowhead in Figure 6C) that is evident after IL-21 stimulation suggests steric
constraints when both proteins are present.
IRF4 Promotes STAT3 Binding
Because of the colocalization of STAT3 and IRF4, we investigated whether STAT3 binding
is affected by IRF4 deficiency. We first examined STAT3 phosphorylation and found no
differences in STAT3 phosphorylation in Irf4+/+ and Irf4−/− CD4+ T cells after IL-21
treatment (Figure 6D). We next used ChIP-Seq to map the STAT3-binding sites on the
whole genome in Irf4−/− CD4+ T cells. As shown in Figure 6E, binding of STAT3 to the
Prdm1, Socs3, Bcl3, and Tha1 genes was greatly diminished in the absence of IRF4.
Moreover, only ~14% of the STAT3-binding sites previously identified (Table S2) were still
present in the Irf4-deficient CD4+ T cells (Table S9), and even those sites were generally
much more weakly seen.
IRF4 Is Critical for Tfh Cell Differentiation
Because STAT3 is a critical mediator for IL-21-induced follicular helper T (Tfh) cell
differentiation (Nurieva et al., 2008; Vogelzang et al., 2008), and we show an IL-21-induced
cooperation of STAT3 and IRF4, we immunized Irf4−/− mice with keyhole limpet
hemocyanin (KLH) to determine the role of IRF4 in Tfh cell differentiation. The proportion
of KLH-induced CXCR5+ICOS+CD4+ Tfh cells was markedly diminished in Irf4−/− mice,
consistent with a role for IRF4 in Tfh cell differentiation (Figures S8A and S8B). As
expected, the proportion of PNA+B220+ germinal center B cells was also low in Irf4−/−
mice (Figures S8C and S8D).
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The TTCnnnTAA Motif that Binds STAT3 in the Prdm1 Gene Is Widely Used
In the Prdm1 IL-21 response element, STAT3 binds to a TTCnnnTAA variant GAS motif.
We thus evaluated the utilization by STAT3 of the canonical TTCnnnGAA GAS motif
versus all single-nucleotide variants in the 4397 STAT3-binding sites observed by ChIP-
Seq. To evaluate the contribution of each motif to STAT3 binding, we measured its distance
in base pairs relative to the maximum of the ChIP-Seq tag density and plotted the
distribution of these distances over all STAT3-binding sites; if a motif binds STAT3, its
position should coincide with the maximum of the tag density. The canonical TTCnnnGAA
GAS motif was the most frequent and best centered (Figure 7A), and its peak is best
approximated by a Gaussian centered at zero, with an accuracy of a single nucleotide. The
TTCnnnTAA/TTAnnnGAA single-base variant found in the Prdm1 gene was the next best
centered, followed by TTCnnnGCA/TGCnnnGAA, whereas other variants were less well
centered. We compared the number of motifs observed in the central versus the marginal
200 bp of each distribution. Only the top three motifs (TTCnnnGAA, TTCnnnTAA/
TTAnnnGAA, and TTCnnnGCA/TGCnnnGAA) were markedly enriched in the center of
the binding sites, and we found no evidence for binding to the other variant motifs (Figure
7B). Thus, the canonical GAS motif and the TTCnnnTAA and TTCnnnGCA variant motifs
are the ones broadly used for binding STAT3 in response to IL-21.
DISCUSSION
We previously demonstrated that IL-21 augments expression of BLIMP1, explaining the
dramatic ability of IL-21 to drive terminal B cell differentiation to plasma cells. To explain
the basis for IL-21-induced BLIMP1 expression, we analyzed the Prdm1 gene and identified
an IL-21 response element ~4.7 kb 3′ of the polyadenylation signal. Importantly, we showed
that both STAT3 and IRF4 bind to this element and are critical for IL-21-induced Prdm1
expression in B and T cells.
IL-21 is known to signal via STAT3 (Diehl et al., 2008; Zeng et al., 2007), but a role for
IRF4 in IL-21 signaling was not clear. Irf4 is an immediate early gene induced in B and T
cells, but it also is highly expressed in plasma cells (Klein et al., 2006; Sciammas et al.,
2006). Although one group reported that IRF4 is not required for LPS-induced Prdm1
induction (Klein et al., 2006), another showed that Irf4−/− B cells have diminished LPS-
induced Prdm1 expression and detected a putative LPS-induced IRF4-binding site in intron
5 (Sciammas et al., 2006). A study of multiple myeloma also found IRF4 binding to the
PRDM1 gene (Shaffer et al., 2008). Although our ChIP-Seq data reveal IRF4-binding sites
within intron 5 for all IRF4-binding sites in mouse CD4+ T cells, this region, which is
included in reporter R6, exhibited little if any IL-21-induced Prdm1 expression. Instead, the
IL-21 response element is 3′ of the gene, suggesting that IL-21 and LPS induce Prdm1
expression via at least partially distinct elements, with our data indicating a functional
cooperation between STAT3 and IRF4.
Although IL-21, IL-6, and IL-10 all activate STAT3, their physiological actions differ,
presumably as a result of when and where the cytokines are produced and their receptors are
expressed. Additionally, they differ in other signaling pathways used and other STATs that
are activated. For example, IL-21 also activates STAT1 and STAT5 as well as ERK and
PI3-kinase-Akt (Zeng et al., 2007). In this study, we showed that IL-21 induced STAT3
phosphorylation more potently than did IL-6 or IL-10, and correspondingly, IL-21 was the
most potent in inducing Socs3 expression in CD4+ T cells. Socs3 expression was also IRF4
dependent, suggesting that STAT3 and IRF4 cooperate for regulating a range of genes.
On the basis of ChIP-Seq analysis, after IL-21 stimulation, STAT3 binds close to IRF4, not
only 3′ of the Prdm1 gene but also at thousands of sites throughout the genome. IRF4 was
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frequently bound to sites prior to IL-21 stimulation, suggesting possibly enhanced binding of
STAT3 to IRF4-occupied sites. Anti-CD3 plus anti-CD28-mediated preactivation of T cells
and anti-CD40 stimulation of B cells can induce Irf4 expression (Basso et al., 2004;
Grumont and Gerondakis, 2000), and consistent with this, the ChIP-Seq data revealed broad
IRF4 binding even before IL-21 treatment and substantial rearrangement of IRF4 binding
after IL-21 treatment. Strikingly, ChIP-Seq analysis with Irf4−/− CD4+ T cells revealed that
IL-21-induced STAT3 binding was dramatically diminished, including in the Prdm1, Socs3,
Bcl3, and Tha1 genes. Thus, IRF4 is critical for optimal STAT3 binding after IL-21
treatment in T cells. Our data indicate that prebound IRF4 may guide STAT3 to specific
binding sites and/or may enhance STAT3 binding. As noted, we were not able to establish a
definitive STAT3-IRF4 physical interaction, although this cannot be excluded, and it is
possible that additional factors might be required for such an interaction. Moreover, it is
possible that the binding of STAT3 is dependent on the overall chromatin structure and that
the presence of IRF4 alters this structure to allow and/or facilitate the binding of STAT3.
IRF4 was previously shown to be critical for Th2 (Lohoff et al., 2002) and Th17 (Brüstle et
al., 2007) cell differentiation. Consistent with IRF4 cooperatively acting with STAT3, which
is known to be important for IL-21-induced Tfh cell differentiation (Nurieva et al., 2008;
Vogelzang et al., 2008), our data indicate that IRF4 may also contribute to Tfh cell
differentiation.
In summary, we have identified an IL-21 response element 3′ to the Prdm1 gene that binds
STAT3 and IRF4, and we show a functional cooperation between these two proteins. ChIP-
Seq genome wide analysis revealed that this effect is not restricted to the Prdm1 gene,
establishing the broad importance of STAT3-IRF4 cooperation. We further show defective
Tfh cell differentiation in Irf4−/− mice analogous to the reported defective Tfh cell
differentiation in Stat3−/− mice. Whether there is broader cooperativity of other STAT
proteins with IRF4 or of STAT3 with other IRF family members is an area for future
investigation. Finally, we have elucidated the relative utilization of canonical versus
noncanonical GAS motifs for STAT3 binding in vivo and demonstrated broad use of a
variant motif that is critical in the Prdm1 IL-21 response element.
EXPERIMENTAL PROCEDURES
Mice and Cell Culture
Animal experiments used protocols approved by the NHLBI Animal Use and Care
Committee and followed NIH guidelines. Details of mice and cell culture are provided in the
Supplemental Experimental Procedures.
Preactivation of Cells and Cytokines
For preactivation of CD4+ T cells, cells were stimulated with 3 µg/ml plate-bound anti-CD3,
1 µg/ml soluble anti-CD28, and 50 U/ml IL-2 for 3 days and rested for 24 hr in fresh RPMI
medium. Cytokines were used at the following concentrations: 100 U/ml IL-2, 50 ng/ml
IL-4, 10 ng/ml IL-5, 10 ng/ml IL-6, 20 ng/ml IL-10, 100 ng/ml IL-21, or 50 ng/ml IFN-γ.
Antibodies
Antibodies to STAT3, STAT5A, and STAT5B were from Zymed (South San Francisco,
CA), antibodies to STAT1, IRF4, IRF8, and PU.1 were from Santa Cruz (Santa Cruz, CA),
and antibodies to CD3ε and CD28 were from PharMingen (San Diego, CA).
Quantitative Real-Time PCR Analysis
This was performed with standard methods (see Supplemental Experimental Procedures).
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Immunoblotting and FACS
For immunoblotting (Kovanen et al., 2008), cell lysates were resolved on 10% Bis-Tris gels
(NuPAGE) and immunoblotted with antibodies to phospho-STAT3 (Cell Signaling
Technology, CA), STAT3 (PharMingen, CA), BLIMP1 (Novus,CO), and β-actin (Santa
Cruz, CA). FACS was performed with standard methods.
Enhancer Constructs, Transient Transfections, and Luciferase Assays
The mouse −979 and +183 Prdm1 promoter fragment was cloned between the HindIII and
XhoI polylinker sites in pGL3-Basic or pGL4-Basic luciferase reporter vectors (Promega,
Madison, WI) (Supplemental Experimental Procedures). A total of 5 × 106 NFS201 cells
were transfected with 5 µg of test plasmid and 40 ng of pRL-TK as a transfection efficiency
control, with use of the DEAE-dextran method. Twenty-four hours later, cells were
stimulated with medium or 50 ng/ml of mouse IL-21 (R&D Systems) for 18 hr. Splenic B
cells, CD4+ T cells, or CD8+ T cells were isolated from 6- to 8-week-old C57BL/6 mice
with anti-B220, anti-CD4, or anti-CD8-microbeads (Miltenyi). B cells were preactivated
with 1 µg/ml anti-CD40 for 3 days, rested for 24 hr, and electroporated (Electropulser, Bio-
Rad) with 20 µg of test plasmid and 10 µg of pRL-TK. Splenic CD4+ and CD8+ T cells
were activated with plate-bound anti-CD3ε (3 µg/ml), soluble anti-CD28 (1 µg/ml), and
IL-2 (50 U/ml) for 3 days, rested for 24 hr, and electroporated with 10 µg of test plasmid
and 5 µg pRL-TK. B and T cells were rested, stimulated with medium or 100 ng/ml mouse
IL-21 for 6 hr, and analyzed for luciferase activity with a luminometer (Victor2 1420
Multilabel Counter; PerkinElmer Life Sciences) and a Dual Luciferase Assay System Kit
(Promega).
Electrophoresis Mobility Shift Assays and Chromatin Immunoprecipitation Assays
These were done by standard methods (see Supplemental Experimental Procedures).
ChIP-Seq Analysis
CD4+ T cells were prepared and ChIP-Seq data were generated as described previously
(Schones et al., 2008). A matched IgG control was associated to each experiment.
Chromatin from 107 cells (~200 ng of DNA) was sonicated into 200–500 bp fragments,
DNA ends were repaired with polynucleotide kinase and Klenow enzyme and treated with
Taq polymerase for generation of a protruding 3′ “A” nucleotide for adaptor ligation. After
ligation of Solexa adaptors, DNA was amplified with the adaptor primers for 17 cycles and
fragments of ~220 bp (mononucleosome + adaptors) were isolated from agarose gels and
used for cluster generation and sequencing on a Solexa 1G and Illumina GA2 Genome
Analyzers. The sequence tags will be available from the NCBI Trace/Short Read Archive
repository. To align sequence tags, analyze their clustering, identify binding motifs, and
display results, we developed new code in C language as extensions of the AceView project
(Thierry-Mieg and Thierry-Mieg, 2006). Each Solexa 25-mer tag was mapped on the mouse
reference genome (version 37), allowing up to two mismatches (single-base insertion,
deletion, or substitution), and retained only if it had a single best position genome-wide.
Each tag was shifted downstream by half the effective length of the sonicated sequenced
fragments, measured as the maximum of the genome-wide correlation function between hits
to the sense and antisense strands of the chromosomes, and represented by a Gaussian with
an area of 1 and σ of 100 bp, which dampens the sampling fluctuations and introduces a
controlled level of fuzziness and “smoothness.” Summing these elementary Gaussians yields
a smoothed tag density. Regions where the density locally exceeds a given threshold are
analyzed. The number of tags was measured after subtracting the local tags from the
matched IgG experiment. If the tag number exceeded a second threshold, it was scored as a
peak. Regions with an IgG peak were deemed nonspecific and eliminated. The peak height
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indicates the protein binding strength. The position of the peak maximum (i.e., the
maximum of the probability of binding the protein) is expected to coincide with the binding
motif. The width covered by the peak (typically 200–600 bp) is the region protected by the
protein or protein complex. Often, in large peaks, one can distinguish subpeaks, which
probably correspond to the binding of multiple proteins. When multiple proteins bind to
overlapping sequences, their peaks are clustered to generate a broader composite binding
site. See Supplemental Experimental Procedures and Figures S4, S5, and S6 for details.
RNA Preparation and Microarray Analysis
Total RNA was prepared with RNeasy (QIAGEN, Valencia, CA). Probes were prepared
with Affymetrix protocols and hybridized to mouse MOE 430 2.0 arrays (Affymetrix, Santa
Clara, CA). The excellent reproducibility across replicas is shown in Figure S2.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Characterization of an IL-21 Response Element 3′ of the Prdm1 Gene
(A) IL-21 induces Prdm1 gene expression. Prdm1 mRNA (means ± SEM of ≥3 independent
experiments, total combined samples ≥4) was determined by quantitative RT-PCR 6 hr after
treatment with 50 ng/ml IL-21.
(B) Cells were activated with 1 µg/ml anti-CD40 and/or 3 µg/ml anti-IgM-Fab for 3 days,
rested 24 hr, and treated with 100 ng/ml IL-21. Prdm1 mRNA (means ± SEM of two
independent experiments, total combined samples = 4) was determined 24 hr later by
quantitative RT-PCR.
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(C) Cells were activated with 1 µg/ml anti-CD40 for 3 days, rested for 24 hr, and treated
with 100 ng/ml IL-21 for 24 hr and immunoblotted with antibodies to BLIMP1 or actin.
Representative results of three independent experiments.
(D) Schematic of the Prdm1 gene (defined by NM_007548 version 2; version 3 of May
2008 starts 61 bp downstream and lacks the 79 bp second exon) and locations of luciferase
reporter constructs. pGL4-pro, minimal promoter (−972 to +183) reporter; K, KpnI; X,
XhoI; S, SmaI; open triangle is the luciferase insertion site in exon 1 for R1, R8, R9, and
R10.
(E) Luciferase assays in NFS201 cells were performed 18 hr after treatment with 50 ng/ml
IL-21.
(F) Shown is luciferase activity 6 hr after treatment with 50 ng/ml IL-21 for NFS201 (means
± SEM of ≥4 independent experiments, total combined samples ≥6) and with 100 ng/ml
IL-21 for splenic B cells (means ± SEM of ≥2 independent experiments, total combined
samples ≥4).
(G and H) More detailed mapping of the Prdm1 IL-21 response element in preactivated
splenic B cells. Shown is luciferase activity 6 hr after treatment with 100 ng/ml IL-21
(means ± SEM of ≥3 independent experiments, total combined samples ≥6).
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Figure 2. STAT3 and IRF4 Bind to the Prdm1 IL-21 Response Element
(A) DNA sequence of the 212 bp (26,237 to 26,448 region relative to the TSS) R37
construct containing the IL-21 response element. The STAT3-binding motif is underlined,
IRF4 and IRF8-binding motifs are boxed, and probes #1, #2, and #3 are indicated.
(B) EMSAs with nuclear extracts from NFS201 cells treated for 7 hr with 50 ng/ml IL-21.
The solid and open arrows indicate IL-21-induced complexes, with the solid arrow
corresponding to the STAT3-DNA complex. The open and closed circles indicate the
supershifted STAT3 and IRF4 complexes, respectively. The WT probe is probe #1 in (A).
(C) EMSAs were performed with probes #2 and #3 (bold and italic sequences in A) with
NFS201 nuclear extracts. The solid arrowhead indicates an IL-21-induced complex, the
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closed circle indicates supershifted IRF4-DNA complexes, and the open arrowhead indicates
a supershifted IRF8-DNA complex.
(D) ChIP was performed with crosslinked splenic B cell lysates prepared 30 min after
treatment with 100 ng/ml IL-21 (means ± SEM). Input was determined by quantitative PCR.
Shown are representative results from two (B and C) or three (D) independent experiments.
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Figure 3. STAT3 and IRF4 Mediate IL-21-Induced Prdm1 Expression in B Cells
(A) Sequences for STAT3 and IRF4-binding motif mutants in the R37 reporter.
(B) Luciferase assays were performed with WT or mutated R37 constructs shown in (A).
Shown is luciferase activity 6 hr after treatment with 100 ng/ml IL-21 (means ± SEM of ≥3
independent experiments, total combined samples ≥ 6).
(C) Prdm1 mRNA expression (means ± SEM of two independent experiments, total
combined samples = 4) was determined in preactivated splenic B cells by quantitative RT-
PCR 24 and 48 hr after treatment with 100 ng/ml IL-21.
(D) Shown is luciferase activity of the R37 construct 6 hr after treatment with 100 ng/ml
IL-21 (means ± SEM of two independent experiments, total combined samples = 4).
(E) IL-21 receptor expression in preactivated and rested Stat3-deficient B cells (dashed line).
The solid line refers to WT mice. The isotype antibody control is shown in gray.
(F) Prdm1 and Pim1 mRNA expression (means ± SEM of ≥3 independent experiments, total
combined samples ≥4) was determined by quantitative RT-PCR 24 hr after treatment with
100 ng/ml IL-21.
(G) IL-21 receptor expression of Irf4−/− B cells (dashed line) and WT control cells (solid
line) was determined. The isotype antibody control is shown in gray.
(H) Splenic B cells were treated with 100 ng/ml IL-21 (means ± SEM of two independent
experiments, total combined samples = 4) and Irf4 expression was determined.
(I) Prdm1 mRNA expression of IL-21 stimulated cells expressing PU.1 (Sfpi1f/f-Cre−/−) or
lacking PU.1 (Sfpi1f/f-Cre−/+) was determined (means ± SEM of two independent
experiments, total combined samples ≥ 4).
(J) IL-21 receptor expression of PU.1-deficient B cells (dashed line) and WT control (solid
line). The isotype antibody control is shown in gray. In (C) and (D), *p < 0.05 (compared
with IL-21-treated WT control mice). In (H), *p < 0.05 for IL-21-treated versus Ctrl.
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Figure 4. STAT3 and IRF4 Control IL-21-Induced Prdm1 Expression in CD4+ T Cells
(A) T cells were preactivated with anti-CD3 plus soluble anti-CD28, and IL-2 for 3 days and
rested for 24 hr in fresh RPMI medium, and Prdm1 mRNA in CD4+ T cells was determined
by quantitative RT-PCR 9, 24, and 48 hr after treatment with IL-2, IL-4, IL-5, IL-6, IL-10,
IL-21, or IFN-γ (see Experimental Procedures for details). Shown are means ± SEM of ≥5
independent experiments (total combined samples ≥10).
(B) Prdm1 mRNA expression was determined in preactivated CD8+ T cells by quantitative
RT-PCR at the indicated times after treatment with 100 ng/ml IL-21.
(C) Preactivated splenic CD4+ and CD8+ T cells were treated with 100 ng/ml IL-21 for 24
hr and BLIMP1 or Actin protein levels were determined by immunnoblotting.
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(D) Luciferase assays were performed with WT or mutated forms of R37 for STAT3 and/or
IRF4-binding motifs 6 hr after treatment of CD4+ T cells with 100 ng/ml IL-21.
(E) ChIP of STAT3 and IRF4 was performed with splenic CD4+ T cell lysates prepared 20
min after treatment with 100 ng/ml IL-21. Input was determined by quantitative PCR.
Results are representative of three independent experiments.
(F) Prdm1 mRNA expression was measured in splenic CD4+ T cells from Stat3f/f-Cre−/− or
Stat3f/f-Cre−/+ mice; cells were not treated or were stimulated with IL-21. The asterisk
indicates no induction as compared to IL-21-treated Stat3f/f-Cre−/− cells.
(G) IL-21R expression was measured in CD4+ T cells from Stat3-deficient (dashed line) or
WT control (solid line) mice. The isotype antibody control is shown in gray.
(H and I) Prdm1 mRNA expression was measured in WT (control), Irf4−/−, and Irf8−/−
CD4+ T cells (H) or CD8+ T cells (I) by quantitative RT-PCR 24 hr after treatment with 0 or
100 ng/ml IL-21mRNA levels (means ± SEM of two independent experiments, total
combined samples = 4). The asterisk indicates decreased induction as compared to Ctrl.
(J) IL-21R expression was measured in CD4+ T cells from Irf4−/− (dashed line) or WT
(solid line) mice. The isotype antibody control is shown in gray.
(K) IL-21 significantly induces Irf4 expression in splenic CD4+ T cells. Cells were treated
with 100 ng/ml IL-21 (means ± SEM of two independent experiments, total combined
samples = 4).
(L) CD4+ T cells were preactivated and then not stimulated or stimulated with IL-21, IL-6,
or IL-10, and subsequently, lysates were immunoblotted with antibodies to phospho-STAT3,
STAT3, or Actin. A representative result from three independent experiments is shown.
(M) CD4+ T cells from Irf4+/+ or Irf4−/− mice were preactivated and then not stimulated or
stimulated with IL-21, IL-6, or IL-10 for 1 or 6 hr. Socs3 mRNA expression (means ± SEM
of two independent experiments, total combined samples = 4) was determined by
quantitative RT-PCR. *p < 0.05 (comparing similar samples to cells from Irf4+/+ and Irf4−/−
mice).
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Figure 5. STAT3- and IRF4-Binding Sites Colocalize
(A) Venn diagram of IRF4-binding sites before and after IL-21 stimulation. Shown are
STAT3 sites after stimulation; the rare STAT3 sites before IL-21 treatment were omitted.
(B) High-resolution mapping of STAT3 and IRF4 ChIP-Seq tags at the Prdm1 IL-21
response element. The number of tags/50 bp is plotted. The 212 bp IL-21 response element
is drawn to scale and exactly overlaps the STAT3 and two IRF4-binding sites. The maxima
of the curves coincide with the essential motifs shown in Figures 3 and 4; the sequences at
these maxima are high-lighted in blue and yellow, with DNA-binding motifs for STAT3 and
IRF4 boxed and underlined, respectively. The shoulder of the largest IRF4 peak suggests a
secondary binding site (gray region).
(C) The mouse Prdm1 gene includes three alternative transcript variants a, b, and c
(AceView at NCBI). The STAT3- and IRF4-binding sites before and after IL-21 treatment
are aligned (scale bar is 10 kb and 20 tags/200 bp window vertically), with binding sites
corresponding to peaks 1–13 (Table S11). Although only one STAT3-IRF4 site (site 12, see
asterisk, shown in detail in B) was found to regulate IL-21-mediated Prdm1 expression,
several other major STAT3 peaks were induced by IL-21, and all overlapped IRF4 peaks. In
intron 5 of variant a, site 9 strongly binds STAT3 but weakly binds IRF4, whereas site 10,
which is 1.59 kb 3′ of site 9, strongly binds IRF4 but weakly binds STAT3. Additionally,
IRF4 associated to the two promoter areas at sites 1 to 5.
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Figure 6. IRF4 Promotes STAT3 Binding In Vivo
(A) CD4+ T cells from Irf4−/− and littermate control mice were preactivated and rested as in
Figure 5A. mRNA for Socs3, Bcl3, and Tha1 determined by quantitative RT-PCR 1 and 6 hr
after treatment with 100 ng/ml IL-21. Shown are means ± SEM of two independent
experiments (total combined samples = 4). *p < 0.05 (compared with WT control mice).
(B) High-resolution mapping of STAT3 and IRF4-ChIP-Seq tags in the Socs3, Bcl3, and
Tha1 genes.
(C) The distance in base pairs between the precise position of IRF4 binding, before (blue) or
after (red) IL-21 treatment, and the precise position of STAT3 binding after IL-21 is plotted
for all composite IRF4- and STAT3-binding sites with >30 tags.
(D) CD4+ T cells from Irf4+/+ and Irf4−/− mice were preactivated and stimulated with 100
ng/ml IL-21 as indicated, followed by immunoblotting with antibodies to phospho-STAT3,
STAT3, or Actin. The representative result of two independent experiments is shown.
(E) High-resolution mapping of the STAT3 ChIP-Seq tags in the Prdm1, Socs3, Bcl3, and
Tha1 genes in CD4+ T cells from Irf4−/− and littermate control mice.
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Figure 7. Distance between the Maxima of STAT3 Binding and GAS or GAS-like Motifs
(A) The presence of TTCnnnGAA GAS motifs and single-nucleotide variants in the 4397
STAT3-binding sites were analyzed genome-wide. The position of each motif relative to the
maximum of STAT3-binding tags (within 250 bp on each side) was recorded and the
distribution over all sites was plotted.
(B) Shown are the number of sites with the motif within 100 bp of maximal STAT3 binding,
the number of observed and expected motifs, assuming a locally flat distribution, and p
value of the observed overrepresentation of each motif in the center (Pearson χ2 test).
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